Conexeu director exercises 500K warrants at $0.001
Conexeu Sciences Inc. (CNXU) director Jeffrey Nathan Sharpe exercised 500,000 Performance Warrants on September 14, 2026, at an exercise price of $0.001 per share, receiving 500,000 shares of Common Stock and bringing his direct holdings to 1,500,000 shares.
Rhea-AI Filing Summary
Conexeu Sciences Inc. (CNXU) director Jeffrey Nathan Sharpe exercised 500,000 Performance Warrants on September 14, 2026, at an exercise price of $0.001 per share, receiving 500,000 shares of Common Stock and bringing his direct holdings to 1,500,000 shares. The exercised Performance Warrants were granted on June 5, 2025 for services, vesting upon a market capitalization milestone, and were structured with a 5-year term to June 5, 2030. The transaction is disclosed as exempt from Section 16(b) under Rule 16b-6(b), and no Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
500,000 shares exercised/converted
Exercise
2 txns
Insider
Sharpe Jeffrey Nathan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Warrants F1, F2 | 500,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 500,000 | $0.001 | $500.00 |
Holdings After Transaction:
Performance Warrants — 500,000 contracts (Direct);
Common Stock — 1,500,000 shares (Direct)
Footnotes (2)
- F1. The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
- F2. The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. The Performance Warrants will vest and be exercisable upon the following milestone events: (i) 500,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed, which have vested; and (ii) 500,000 Performance Warrants upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.
Key Figures
Performance Warrants Exercised: 500,000 warrants
Exercise Price: $0.001 per share
Common Shares Acquired: 500,000 shares
+4 more
7 metrics
Performance Warrants Exercised
500,000 warrants
Exercised by director on September 14, 2026
Exercise Price
$0.001 per share
Exercise price of Performance Warrants granted June 5, 2025
Common Shares Acquired
500,000 shares
Common Stock received upon warrant exercise on September 14, 2026
Common Shares Held After Transaction
1,500,000 shares
Director’s direct Common Stock holdings after the September 14, 2026 exercise
Warrant Term
5 years
Performance Warrants granted June 5, 2025, expiring June 5, 2030
Market Capitalization Milestone
$80,000,000
Required market cap for 500,000 Performance Warrants to vest after 20 consecutive trading days
Vesting Trading Days Requirement
20 trading days
Consecutive trading days at or above the $80,000,000 market capitalization milestone
Key Terms
Performance Warrants, Section 16(b), Rule 16b-6(b), market capitalization, +1 more
5 terms
Performance Warrants financial
"The Performance Warrants were granted on June 5, 2025 and have an exercise price"
Section 16(b) regulatory
"The transaction is also exempt from Section 16(b) of the Securities Exchange"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-6(b) regulatory
"pursuant to Rule 16b-6(b) promulgated under the Act"
market capitalization financial
"trading for at least 20 consecutive trading days at a market capitalization of"
Market capitalization is the total market value of a company’s outstanding shares, calculated by multiplying the current share price by the number of shares issued. It gives a quick snapshot of a company’s size and how investors value it, influencing perceived risk, index membership, and roughly how much it might cost to buy the whole company — like using a sticker price to compare the relative size and price of different houses.
510(k) application medical
"500,000 Performance Warrants upon the Issuer submitting a 510(k) application"
A 510(k) application is a regulatory submission to the U.S. Food and Drug Administration showing that a new medical device is substantially similar to an already approved device, so it can be cleared for marketing without the longest, most rigorous approval process. For investors, a cleared 510(k) means faster, lower-cost market access and lower regulatory risk compared with full approvals, which can speed revenue and reduce uncertainty — like getting permission to sell a new model because it’s close to an existing one.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Conexeu Sciences Inc. (CNXU) report on this Form 4?
Conexeu Sciences Inc. reported that director Jeffrey Nathan Sharpe exercised 500,000 Performance Warrants on September 14, 2026, at an exercise price of $0.001 per share, receiving 500,000 shares of Common Stock in the transaction.
What are the key terms of the Performance Warrants reported by CNXU?
The Performance Warrants were granted on June 5, 2025, have an exercise price of $0.001 and a 5-year term to June 5, 2030. They were granted for services and required no purchase price for the warrants themselves.
What milestone triggered vesting of the exercised CNXU Performance Warrants?
The exercised 500,000 Performance Warrants vested upon Conexeu Sciences Inc.’s listed common shares trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized North American stock exchange.
How is the CNXU warrant exercise treated under Section 16(b)?
The filing states that the transaction is exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-6(b), which addresses the treatment of derivative security exercises for short-swing profit purposes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
